ZLAB Stock - Zai Lab Limited
Unlock GoAI Insights for ZLAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $398.99M | $266.72M | $215.04M | $144.31M | $48.96M |
| Gross Profit | $251.13M | $170.90M | $141.02M | $92.07M | $-190,489,000 |
| Gross Margin | 62.9% | 64.1% | 65.6% | 63.8% | -389.1% |
| Operating Income | $-282,117,000 | $-366,573,000 | $-404,357,000 | $-700,064,000 | $-301,801,000 |
| Net Income | $-257,103,000 | $-334,620,000 | $-443,286,000 | $-704,471,000 | $-268,905,000 |
| Net Margin | -64.4% | -125.5% | -206.1% | -488.2% | -549.3% |
| EPS | $-2.60 | $-34.60 | $-46.30 | $-75.80 | $-34.60 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2025 | Jefferies | Resumed | Buy | $52 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $55 |
| March 3rd 2025 | BofA Securities | Downgrade | Neutral | $36.1← $29 |
| December 14th 2023 | Morgan Stanley | Initiation | Overweight | $47.5 |
| August 10th 2023 | Cantor Fitzgerald | Initiation | Overweight | $70 |
Earnings History & Surprises
ZLABEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.28 | $-0.33 | -17.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.37 | $-0.37 | 0.0% | = MET |
Q2 2025 | May 8, 2025 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.61 | $-0.80 | -31.1% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.75 | $-0.42 | +44.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.66 | $-0.82 | -24.2% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.93 | $-0.55 | +40.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.87 | $-0.98 | -12.6% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.94 | $-0.71 | +24.5% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.74 | $-1.25 | -68.9% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-1.04 | $-0.65 | +37.5% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.04 | $-0.65 | +37.5% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.20 | $-1.68 | -40.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.95 | $-1.44 | -51.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-1.22 | $-0.86 | +29.5% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-22.19 | — | — |
Q4 2021 | Nov 9, 2021 | $-1.24 | $-1.01 | +18.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.55 | $-1.76 | -13.5% | ✗ MISS |
Latest News
Zai Lab Begins First Human Trial of New Eczema Drug Candidate ZL-1503
📈 PositiveReported Sunday, Zai Lab Announces 2025 NRDL Renewals For VYVGART, NUZYRA Oral Formulation, And ZEJULA, Expanding Patient Access In Greater China
📈 PositiveUPDATE: Zai Lab FY2025 Revenue expected to be more than $460.000M vs $550.397M Est
📉 NegativeZai Lab Lowers FY2025 Sales Guidance from $560.000M-$590.000M to $460.000M vs $550.397M Est
📉 NegativeZai Lab Q3 EPADS $(0.33) Misses $(0.05) Estimate, Sales $116.095M Miss $136.703M Estimate
📉 NegativeZai Lab Demonstrates Robust, Durable Responses In Phase 1 Clinical Study Of Zocilurtatug Pelitecan In Pre-Treated Participants With Extensive-Stage Small Cell Lung Cancer Across Six Dose Groups
📈 PositiveZai Lab Reveals Oral Presentation Of Updated Data From Global Phase 1 Trial Of Zocilurtatug Pelitecan (ZL-1310), A Potential First-In-Class DLL3-Targeted ADC, At 2025 AACR-NCI-EORTC Conference
📈 PositiveReported Sunday, Zai Lab Announces Hong Kong Approval Of TIVDAK for Adult Patients With Recurrent Or Metastatic Cervical Cancer After Chemotherapy
📈 PositiveZai Lab Granted Innovative Medical Device Designation By China National Medical Products Administration For Tumor Treating Fields In Pancreatic Cancer
📈 PositiveFrequently Asked Questions about ZLAB
What is ZLAB's current stock price?
What is the analyst price target for ZLAB?
What sector is Zai Lab Limited in?
What is ZLAB's market cap?
Does ZLAB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZLAB for comparison